This National Research and Demonstration Center will be directed toward the acquisition of new basic and clinical knowledge about transfusion transmitted diseases, toward lowering the risks for patients through development and application of measures which can be applied to the blood resource and its management; toward reducing the exposure to risks of patients who must be transfused, through the use of safer, higher efficacy protocols; and toward the elimination of transfusion in other cases. Through demonstrations and education, the Center will test the effectiveness of a program to conserve blood and reduce donor exposure by increasing physician awareness of the dangers of transfusion, and by accelerating the inclusion of safer modalities for patients who must be transfused, specifically by seeking to increase the use of autologous blood and the vigorous practice of state-of-the-art conservation. The SCOR component includes 5 research projects, four of which will study aspects of blood borne infectious agents, including AIDS, HTLV, CMV and HB. The fifth will investigate national trends in transfusion practice with the view to analyzing national policy alternatives and providing reliable information about use of the national blood resource to the public. The Integration Component of the NRDC will function to provide overall management and direction of the Center and unify its programmatic thrust toward reducing the risk of transfusion transmitted infections for patients who become candidates for transfusion; conserve the blood resource, thus moderating the demands upon blood donors to give blood; and, for those patients who are chronically dependent upon blood or blood components, to increase the safety and efficacy of the products they need.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL033774-05
Application #
3106719
Study Section
(SRC)
Project Start
1985-09-30
Project End
1990-12-31
Budget Start
1989-09-30
Budget End
1990-12-31
Support Year
5
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Immune Disease Institute, Inc.
Department
Type
DUNS #
115524410
City
Boston
State
MA
Country
United States
Zip Code
02115
Churchill, W H; McGurk, S; Chapman, R H et al. (1998) The Collaborative Hospital Transfusion Study: variations in use of autologous blood account for hospital differences in red cell use during primary hip and knee surgery. Transfusion 38:530-9
Wallace, E L; Churchill, W H; Surgenor, D M et al. (1998) Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 38:625-36
Ringer, S A; Richardson, D K; Sacher, R A et al. (1998) Variations in transfusion practice in neonatal intensive care. Pediatrics 101:194-200
Surgenor, D M; Churchill, W H; Wallace, E L et al. (1998) The specific hospital significantly affects red cell and component transfusion practice in coronary artery bypass graft surgery: a study of five hospitals. Transfusion 38:122-34
Surgenor, D M; Churchill, W H; Wallace, E L et al. (1996) Determinants of red cell, platelet, plasma, and cryoprecipitate transfusions during coronary artery bypass graft surgery: the Collaborative Hospital Transfusion Study. Transfusion 36:521-32
Wang, W K; Mayer, K H; Essex, M et al. (1996) Sequential change of cysteine residues in hypervariable region 1 of glycoprotein 120 in primary HIV type 1 isolates of subtype B. AIDS Res Hum Retroviruses 12:1195-7
Essex, M (1996) Retroviral vaccines: challenges for the developing world. AIDS Res Hum Retroviruses 12:361-3
Wang, W K; Essex, M; Lee, T H (1996) Single amino acid substitution in constant region 1 or 4 of gp120 causes the phenotype of a human immunodeficiency virus type 1 variant with mutations in hypervariable regions 1 and 2 to revert. J Virol 70:607-11
Soto-Ramirez, L E; Renjifo, B; McLane, M F et al. (1996) HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 271:1291-3
Wang, W K; Essex, M; McLane, M F et al. (1996) Pattern of gp120 sequence divergence linked to a lack of clinical progression in human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A 93:6693-7

Showing the most recent 10 out of 98 publications